Protagonist Therapeutics (PTGX) Stock Price Target 2026

See analyst price targets, ratings and recent upgrades and downgrades for Protagonist Therapeutics (PTGX) stock.

Latest Upgrades and Downgrades for Protagonist Therapeutics Stock

Date	Firm	Analyst	Action	Rating Change	Price Target
—	HC Wainwright & Co.	Douglas Tsao	PT Raise	Buy	$170→$221
—	TD Cowen	Tara Bancroft	PT Raise	Buy	$155→$160
—	UBS	Alice Nettleton	Initiate	Buy	$184
—	Leerink Partners	Will Soghikian	Assumes	Outperform	$150→$190
—	Barclays	Etzer Darout	PT Raise	Overweight	$153→$180
—	BMO Capital	Etzer Darout	PT Raise	Outperform	$178→$190
—	Citigroup	Geoff Meacham	PT Raise	Buy	$175→$182
—	HC Wainwright & Co.	Douglas Tsao	PT Raise	Buy	$167→$170
—	BMO Capital	Etzer Darout	PT Raise	Outperform	$112→$178
—	Truist Securities	Srikripa Devarakonda	PT Raise	Buy	$145→$170
—	Wedbush	Yun Zhong	PT Raise	Outperform	$118→$173
—	Goldman Sachs	Richard Law	Upgrade	Neutral→Buy	$110→$186
—	Citigroup	Geoff Meacham	PT Raise	Buy	$130→$175
—	Barclays	Etzer Darout	PT Raise	Overweight	$151→$153
—	Barclays	Etzer Darout	PT Raise	Overweight	$119→$151
—	Truist Securities	Srikripa Devarakonda	PT Raise	Buy	$121→$145
—	Citigroup	Geoff Meacham	PT Raise	Buy	$125→$130
—	Citizens	Jonathan Wolleben	PT Raise	Market Outperform	$120→$137
—	Wedbush	Yun Zhong	PT Raise	Outperform	$112→$118
—	Truist Securities	Srikripa Devarakonda	PT Raise	Buy	$110→$121

Analyst Ratings News

PRO
HC Wainwright & Co. Maintains Buy on Protagonist Therapeutics, Raises Price Target to $221

HC Wainwright & Co. analyst Douglas Tsao maintains Protagonist Therapeutics (NASDAQ:PTGX) with a Buy and raises the price target from $170 to $221.

Benzinga Newsdesk

PRO
TD Cowen Maintains Buy on Protagonist Therapeutics, Raises Price Target to $160

TD Cowen analyst Tara Bancroft maintains Protagonist Therapeutics (NASDAQ:PTGX) with a Buy and raises the price target from $155 to $160.

Benzinga Newsdesk

PRO
UBS Initiates Coverage On Protagonist Therapeutics with Buy Rating, Announces Price Target of $184

UBS analyst Alice Nettleton initiates coverage on Protagonist Therapeutics (NASDAQ:PTGX) with a Buy rating and announces Price Target of $184.

Benzinga Newsdesk

PRO
Leerink Partners Assumes Protagonist Therapeutics at Outperform, Raises Price Target to $190

Leerink Partners analyst Will Soghikian assumes Protagonist Therapeutics (NASDAQ:PTGX) with a Outperform rating and raises Price Target to $190.

Benzinga Newsdesk

PRO
Barclays Maintains Overweight on Protagonist Therapeutics, Raises Price Target to $180

Barclays analyst Etzer Darout maintains Protagonist Therapeutics (NASDAQ:PTGX) with a Overweight and raises the price target from $153 to $180.

Benzinga Newsdesk

Apple To $303? Here Are 10 Top Analyst Forecasts For Tuesday

Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades and downgrades, please see our analyst ratings page. Cantor Fitzgerald raised

Avi Kapoor

Protagonist Therapeutics Inc

Protagonist Therapeutics (PTGX) Stock Price Target 2026

Latest Upgrades and Downgrades for Protagonist Therapeutics Stock

Protagonist Therapeutics (PTGX) Stock Price Target 2026

Latest Upgrades and Downgrades for Protagonist Therapeutics Stock

Analyst Ratings News

PRO
HC Wainwright & Co. Maintains Buy on Protagonist Therapeutics, Raises Price Target to $221

PRO
TD Cowen Maintains Buy on Protagonist Therapeutics, Raises Price Target to $160

PRO
UBS Initiates Coverage On Protagonist Therapeutics with Buy Rating, Announces Price Target of $184

PRO
Leerink Partners Assumes Protagonist Therapeutics at Outperform, Raises Price Target to $190

PRO
Barclays Maintains Overweight on Protagonist Therapeutics, Raises Price Target to $180

Apple To $303? Here Are 10 Top Analyst Forecasts For Tuesday

People Also Watch

People Also Watch

Analyst Ratings News

PRO
HC Wainwright & Co. Maintains Buy on Protagonist Therapeutics, Raises Price Target to $221

PRO
TD Cowen Maintains Buy on Protagonist Therapeutics, Raises Price Target to $160

PRO
UBS Initiates Coverage On Protagonist Therapeutics with Buy Rating, Announces Price Target of $184

PRO
Leerink Partners Assumes Protagonist Therapeutics at Outperform, Raises Price Target to $190

PRO
Barclays Maintains Overweight on Protagonist Therapeutics, Raises Price Target to $180

Apple To $303? Here Are 10 Top Analyst Forecasts For Tuesday

Protagonist Therapeutics Inc

Protagonist Therapeutics (PTGX) Stock Price Target 2026

Latest Upgrades and Downgrades for Protagonist Therapeutics Stock

Protagonist Therapeutics (PTGX) Stock Price Target 2026

Latest Upgrades and Downgrades for Protagonist Therapeutics Stock

Analyst Ratings News

PROHC Wainwright & Co. Maintains Buy on Protagonist Therapeutics, Raises Price Target to $221

PROTD Cowen Maintains Buy on Protagonist Therapeutics, Raises Price Target to $160

PROUBS Initiates Coverage On Protagonist Therapeutics with Buy Rating, Announces Price Target of $184

PROLeerink Partners Assumes Protagonist Therapeutics at Outperform, Raises Price Target to $190

PROBarclays Maintains Overweight on Protagonist Therapeutics, Raises Price Target to $180

Apple To $303? Here Are 10 Top Analyst Forecasts For Tuesday

People Also Watch

People Also Watch

Analyst Ratings News

PROHC Wainwright & Co. Maintains Buy on Protagonist Therapeutics, Raises Price Target to $221

PROTD Cowen Maintains Buy on Protagonist Therapeutics, Raises Price Target to $160

PROUBS Initiates Coverage On Protagonist Therapeutics with Buy Rating, Announces Price Target of $184

PROLeerink Partners Assumes Protagonist Therapeutics at Outperform, Raises Price Target to $190

PROBarclays Maintains Overweight on Protagonist Therapeutics, Raises Price Target to $180

Apple To $303? Here Are 10 Top Analyst Forecasts For Tuesday

PRO
HC Wainwright & Co. Maintains Buy on Protagonist Therapeutics, Raises Price Target to $221

PRO
TD Cowen Maintains Buy on Protagonist Therapeutics, Raises Price Target to $160

PRO
UBS Initiates Coverage On Protagonist Therapeutics with Buy Rating, Announces Price Target of $184

PRO
Leerink Partners Assumes Protagonist Therapeutics at Outperform, Raises Price Target to $190

PRO
Barclays Maintains Overweight on Protagonist Therapeutics, Raises Price Target to $180

PRO
HC Wainwright & Co. Maintains Buy on Protagonist Therapeutics, Raises Price Target to $221

PRO
TD Cowen Maintains Buy on Protagonist Therapeutics, Raises Price Target to $160

PRO
UBS Initiates Coverage On Protagonist Therapeutics with Buy Rating, Announces Price Target of $184

PRO
Leerink Partners Assumes Protagonist Therapeutics at Outperform, Raises Price Target to $190

PRO
Barclays Maintains Overweight on Protagonist Therapeutics, Raises Price Target to $180